IRCT20150303021315N32招募中3 期
A phase III, randomized, multicenter, double-blind, two-armed, parallel, active-controlled, non-inferiority clinical trial to compare efficacy and safety of Evolocumab (CinnaGen) versus Evolocumab (Repatha®, Amgen Inc.) in patients with hyperlipidemia receiving concurrent high intensity statin
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 75 years（—）
- 性别
- All
入选标准
- •Male or female =18 to =75 years of age
- •Willingness for signing and having signed the informed consent form
- •Should have received an approved high intensity statin at a stable daily dose, at least 4 weeks before screening, and has not achieved the target LDL-C level
- •Having Established Atherosclerotic Cardiovascular Disease (ASCVD) (secondary prevention) or patients without established ASCVD (primary prevention) who are categorized as very high risk” in ASCVD risk assessment according to AACE/ACE 2020 guideline ASCVD is defined as diagnosis of myocardial infarction, diagnosis of non-hemorrhagic stroke (TIA does not qualify as stroke for inclusion), symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) greater than 0.85, or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease.- ”Very high risk” in ASCVD risk assessment is defined as followed:•Diabetes with at least 1 risk factor(s)• CKD greater than or equal to 3 with albuminuria (assessed by urine albumin/urine creatinine ratio) • HeFH
- •Fasting LDL-C as determined by the central laboratory at screening equal or greater than 70 milligram per deciliter
- •Fasting triglycerides less than or equal to 400 milligram per deciliter
排除标准
- •New York Heart Association (NYHA) III or IV heart failure or LVEF less than 30%
- •Uncontrolled hypertension (SBP more than 180 mmHg or DBP>110 mm Hg)
- •Type 1 diabetes, newly diagnosed or poorly controlled type 2 diabetes (HbA1c more than 8.5%)
- •Active pancreatitis
- •Uncontrolled serious cardiac arrhythmia less or equal to 3 months prior to randomization
- •History of myocardial infarction/unstable angina, PCI (percutaneous coronary intervention), CABG, or stroke less or equal 3 months prior to randomization
- •Have inadequate organ and marrow function as indicated by laboratory values:•TSH less than LLN or TSH more than1.5×ULN (in addition to abnormal free T4)•eGFR<30 mL/min/1.73m2•AST or ALT more than 3×ULN•CK more than 5×ULN
- •Active infection
- •Hepatitis C infection
- •History of deep vein thrombosis or pulmonary embolism less or equal 3 months prior to randomization
- •Administration of bile acid-sequestering resins, statins (outside of study regimen), ezetimibe, fibrates, less than 200 mg/day niacin, or more than 1000 milligram/day omega-3 fatty acids less or equal to 6 weeks prior to randomization
- •Administration of cyclosporine, systemic steroids, vitamin A derivatives and retinol derivatives for the treatment of dermatologic conditions (except for the purpose of supplementation) less than 3 months prior to randomization
- •Prohibited procedures such as cardiac surgery or revascularization, any weight loss procedure (e.g., bariatric surgery) within 3 months prior to randomization, or receiving any major organ transplant (e.g., lung, liver, heart, bone marrow and renal), LDL or plasma apheresis within 12 months prior to randomization
- •Personal or family history of hereditary muscular disorders
- •Major hematologic, metabolic, or GI disruption
- •A female subject who is pregnant or breast feeding, or planning to become pregnant while enrolled in the study
- •Previously received Evolocumab or any other investigational therapy to inhibit PCSK9
- •On a dietary regimen which is significantly deviated from recommended diet by physician (e.g., high levels of carbohydrates or lipids, low fiber regimens, or regular alcohol consumption)
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
研究者
相似试验
进行中（未招募）
1 期
Adjuvant Ribociclib with Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1).Hormone receptor-positive, Estrogen and/or progesterone receptor-positive, HER2-negative, High risk early breast cancerMedDRA version: 20.0Level: LLTClassification code 10006203Term: Breast cancer stage unspecifiedSystem Organ Class: 100000020819MedDRA version: 20.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000115074EUCTR2014-001795-53-GRovartis Pharma AG2,000
招募中
3 期
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerCancerPACTR202402608766452Roche4
尚未招募
3 期
The clinical study assessing safety of medicine containing two antiemetic drugs compared to safety of other antiemetic drugs (aprepitant, oral palonosetron)given with oral dexamethasone when they are administered to prevent nausea,vomiting in cancer patients receiving multiple chemotherapy cyclesCTRI/2012/01/002343Helsinn Healthcare SA400
进行中（未招募）
1 期
Multicenter study to evaluate the effect and safety of oral vancomycin compared with placebo in the prevention of relapse due to Clostridium difficile infection in patients treated with antibiotics administered systemically.Patients at high risk of recurrence due to CDI who require hospitalization and who increase morbidity and mortality from new CDI.MedDRA version: 20.0Level: LLTClassification code 10072994Term: Clostridium difficile infection recurrenceSystem Organ Class: 100000004862EUCTR2019-002677-57-ESDra. Julia Origüen Sabater108
已完成
3 期
A phase III, multicenter, randomized, double-blind placebo-controlled study to assess the efficacy and safety of Tocilizumab in subjects with giant cell arteritis.Giant Cell Arteritis10027665Temporal ArteritisNL-OMON39663Hoffmann-La Roche18